AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.

AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and ...

AbbVie (NYSE: ABBV) recently announced that its immunology drug Rinvoq had received approval from the European Commission (EC) to treat adolescent and adult patients with moderate-to-severe atopic ...

AbbVie has pegged multibillion-dollar hopes on Rinvoq to fill the revenue gap when immunology superstar Humira loses U.S. market exclusivity. But that plan, dependent on multiple label expansions ...

Now, as a rheumatoid arthritis drug developed at the Worcester facility hits the market, AbbVie — with 1,200 employees in the city — is looking for further expansion, said Lisa Olson, the vice ...

AbbVie is transitioning immunology sales to new and more effective treatments, ... (up 24%) continues to benefit from label expansion into major depression.

The company expects its newer immunology duo of Rinvoq and Skyrizi to pull down $27 billion by 2027, far eclipsing Humira's 2022 peak of $21 billion. Last year, the duo generated nearly $12 billion.

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion.

Wells Fargo analyst Mohit Bansal has maintained their bullish stance on ABBV stock, giving a Buy rating today. Mohit Bansal has given his Buy rating due to a combination of factors that enhance ...

Driven by AbbVie's profit-maximization catalysts mentioned earlier, adjusted earnings per share came in at $3.31, 13.3% higher compared to the prior-year period.With AbbVie's biopharmaceutical ...